newsfilter
← Latest News
Business Wire·

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in